Flex Pharma (FLKS) Stock Price, News & Analysis

Company Overview

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT products online through its direct-to-consumer Website and through third-party Websites, including a retailer that offers international shipping. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $0.76 to $0.84
• 50-Day Range: $0.57 to $14.51
• 52-Week Range: $0.26 to $1.49
• Volume: 14,556 shs
• Average Volume: 2.03 million shs
• Market Capitalization: $15.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FLKS Stock Analysis - Frequently Asked Questions

How were Flex Pharma's earnings last quarter?

Flex Pharma Inc (NASDAQ:FLKS) posted its earnings results on Wednesday, May, 1st. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.11 million for the quarter. Flex Pharma had a negative trailing twelve-month return on equity of 98.04% and a negative net margin of 1,208.42%.

When did Flex Pharma IPO?

Flex Pharma (FLKS) raised $60 million in an initial public offering on Thursday, January 29th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.

What other stocks do shareholders of Flex Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Flex Pharma investors own include Micron Technology (MU), Ocular Therapeutix (OCUL), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), Celldex Therapeutics (CLDX), Gilead Sciences (GILD) and Histogenics (HSGX).

Company Calendar

• Last Earnings: 5/01/2019
• Today: 5/28/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FLKS
• CIK: 1615219
• Web: www.flex-pharma.com
• Phone: 617-874-1821
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.92 million
• Net Margins: -1,208.42%
• Pretax Margin: N/A
• Return on Equity: -98.04%
• Return on Assets: -83.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.86
• Quick Ratio: 6.74

Sales & Book Value

• Annual Sales: $840,000.00
• Price / Sales: 17.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.51 per share
• Price / Book: 1.64

Miscellaneous

• Outstanding Shares: 18,070,000
• Free Float: N/A
• Market Cap: $15.08 million
• Optionable: Not Optionable
• Beta: 1.65